bortezomib viatris 3.5 mg inj. sol. (pwdr.) s.c./i.v. vial
viatris gx bv-srl - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib sandoz 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial
sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib sandoz 1 mg inj. sol. (pwdr.) i.v. vial
sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 1 mg - powder for solution for injection - 1 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib teva 1 mg inj. sol. (pwdr.) i.v. vial
teva pharma belgium sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 1 mg - powder for solution for injection - 1 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib teva 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial
teva pharma belgium sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib teva 1 mg
abic marketing ltd, israel - bortezomib - powder for solution for injection - bortezomib 1 mg - bortezomib - bortezomib teva is indicated for the treatment of patients with multiple myeloma. bortezomib teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
bortezomib inovamed 3.5 mg
inovamed ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib inovamed is indicated for the treatment of patients with multiple myeloma.bortezomib inovamed is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib inovamed in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
bortezomib teva 2.5 mg
abic marketing ltd, israel - bortezomib - powder for solution for injection - bortezomib 2.5 mg - bortezomib - bortezomib teva is indicated for the treatment of patients with multiple myeloma. bortezomib teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation
bortezomib sandoz 2,5 mg inj. sol. (pwdr.) i.v./s.c. vial
sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg - powder for solution for injection - 2,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib waverley pharma europe 1 mg inj. sol. (pwdr.) i.v. vial
waverley pharma europe ltd. - bortezomib mannitol boronic ester - eq. bortezomib 1 mg - powder for solution for injection - 1 mg - bortezomib mannitol boronic ester - bortezomib